Oxaliplatin is available as a 5-mg/mL concentrated solution in 10-, 20-, and 40-mL single-use vials.2852; 2853
Oxaliplatin is also available in single-use vials containing 50 or 100 mg of lyophilized drug and lactose monohydrate as an excipient.2854 Reconstitute the 50- or 100-mg vials with 10 or 20 mL, respectively, of water for injection or dextrose 5%.2854
Trade Name(s)
Eloxatin
For intravenous infusion, both the concentrated injection and the reconstituted solution must be diluted in 250 to 500 mL of dextrose 5% prior to administration.2852; 2853; 2854 Chloride-containing solutions must not be used for reconstitution2854 or dilution.2852; 2853; 2854
Oxaliplatin is administered by intravenous infusion over 2 hours.2852; 2853; 2854
Contact of oxaliplatin solutions with aluminum in needles or metal parts of administration equipment should be avoided.2852; 2853; 2854 Aluminum has caused degradation of some platinum compounds.2852; 2853; 2854
Intact vials of both formulations are stored at controlled room temperature.2852; 2853; 2854 Protect vials of the concentrated solution from light by storing in the outer carton, and do not freeze.2852; 2853 Vials of the lyophilized formulation and solutions diluted for infusion do not require light protection.2852; 2853; 2854
Following reconstitution of the lyophilized oxaliplatin formulation in the original vial, the resulting solution may be stored up to 24 hours under refrigeration.2854
After final dilution of either formulation for administration in 250 to 500 mL of dextrose 5%, the manufacturers indicate that the drug is stable for six hours at room temperature or for 24 hours under refrigeration.2852; 2853; 2854 However, Sanofi stated that oxaliplatin diluted in dextrose 5% for infusion was stable for 24 hours at room temperature; at a concentration of 3 g/L, the drug was stated to be stable for at least five days at room temperature.2623
pH Effects
Oxaliplatin is incompatible with alkaline drugs and solutions and should not be mixed with or administered simultaneously with them.2852; 2853; 2854 Administration lines should be flushed with dextrose 5% prior to administering any other medication.2852; 2853; 2854
Y-Site Injection Compatibility (1:1 Mixture)
Additional Compatibility Information
Infusion Solutions
Stability of oxaliplatin (Accord) 0.1 mg/mL in dextrose 5% (Braun), sodium chloride 0.9% (Braun), Ringer’s injection, lactated (Braun), Dianeal PD-4 with dextrose 1.36% (Baxter), and phosphate buffer (pH 7.4) 0.14 M at 42°C was evaluated for use of the drug as hyperthermic intraperitoneal chemotherapy.3524 Less than 10% oxaliplatin loss occurred in 2 hours in dextrose 5%.3524 In phosphate buffer and Dianeal PD-4 with dextrose 1.36%, drug losses of less than 10% occurred within 30 minutes; however, losses exceeded 10% by 2 hours.3524 In Ringer’s injection, lactated and sodium chloride 0.9%, the solutions with the greatest chloride ion concentrations, drugs losses exceeded 10% as early as 30 minutes and losses of 18 and 21%, respectively, occurred within 2 hours.3524
For a list of references cited in the text of this monograph, search the monograph titled References.